Efficacy of pegylated interferon plus ribavirin lead-in therapy on telaprevir with pegylated interferon plus ribavirin therapy for aged patients with chronic hepatitis C genotype 1 - Efficacy of pegylated interferon plus ribavirin lead-in therapy on telaprevir with pegylated interferon plus ribavirin therapy

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine0 个研究点目标入组 410 人开始时间: 2012年2月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with co-infection with hepatitis B virus and positive of HBs antigen 2) Patients with co-infection with human immunodeficiency virus 3) Patients with alcoholic liver disorder or autoimmune hepatitis 4) Patients with uncompensated cirrhosis or hepatic failure 5) Patients with multiple organ failure or immunological deficiency 6) Patients with severe depression or past history of psychiatric disorder 7) Patients with chronic renal failure or less than 50 ml/min of creatinine clearance 8) Patients whose hemoglobin levels are less than 12 g/dL 9) Patients whose platelet counts are less than 15,000 /microL 10) Patients whose neutrophil counts are less than 1,500 /microL 11) Patients whom investigator disqualified

发起方

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine